PainChek finds sharper growth path in residential aged care

PainChek narrows its commercial bet

PainChek Ltd (ASX:PCK) is trading breadth for focus. The AI-powered pain assessment company has made residential aged care its immediate commercial priority, concentrating resources on markets where it says the product has established clinical evidence, customer use and care-workflow experience. The shift comes with a new chief executive, a strengthened US sales presence and board renewal, but also a clear financial constraint: the company ended September with A$4.269 million in cash and no unused financing facilities.

The quarter delivered encouraging top-line movement, though not a clean acceleration across every measure. Unaudited customer revenue rose 12.9% from June to A$1.210 million and 42.4% year on year. Customer retention improved from 85% to 90%, while cumulative assessments reached 24.49 million. Yet activated licences and activated annual recurring revenue each increased only 1.2% quarter on quarter, to 91,323 licences and A$4.514 million respectively.

US and UK contracts sit outside current ARR

The more consequential commercial developments are still moving through PainChek’s contract-to-cash machinery. The company’s Sabra expansion to 23 sites, covering 808 memory care licences across five operators, is targeted for implementation, training and activation by 31 December 2026. Those licences will contribute to ARR when activated, rather than when signed.

In the US, a paid Silverado pilot covers two sites and 203 licences within a wider opportunity of up to 2,500 licences across the operator’s 31 sites. Any wider rollout depends on the pilot’s evaluation and additional agreements. PainChek is also in discussions with larger US groups, but those conversations are not signed commitments.

The UK provides another sizeable test of execution. The Hallmark contract for 1,800 licences covers all 23 of the operator’s homes across England and Wales, with implementation due to begin in late January 2027 and full rollout expected by 30 June. The agreement is separate from the September-quarter activated base, so its commercial value will depend on homes and licences moving through the planned deployment schedule.

Leadership reset accompanies the sales push

Chief executive Karen Holzberger started on 17 August and is based in the United States. PainChek has also expanded David Allsopp’s responsibilities to cover US commercial activity, appointed Joseph Farmborough as chief technology and innovation officer, and added sales coverage in the US and UK. Lil Bianchi, appointed non-executive chair in May, is overseeing the broader renewal process, which includes finding directors with international healthcare commercialisation and US growth experience.

The strategy is deliberately narrower than the company’s total addressable market estimate of A$769.6 million across 9.27 million potential licences. Hospitals, skilled nursing and home care remain in development, with deeper PointClickCare integration still subject to technical agreement and delivery. PainChek also said it would review the home-care opportunity once greater clarity on reimbursement changes emerges, expected by the second quarter of calendar 2027. Participation in the Mayo Clinic Platform Accelerate programme offers a pathway to explore hospital and acute-care opportunities, but is not a customer contract.

Cash pressure puts conversion under scrutiny

Net operating cash outflow was A$1.714 million in the quarter, helped by A$1.136 million of government grants and tax incentives. Excluding that receipt, the company said the outflow would have been A$2.850 million. Customer receipts fell 18.6% from June to A$1.045 million, reflecting the timing of renewals and collections, while staff and administration payments rose during the leadership transition and recruitment process.

The Appendix 4C’s 2.5-quarter funding estimate is based on the September cash outflow, includes the government support and is not a forecast of future requirements. PainChek also has A$5.5 million of unsecured convertible notes, fully drawn in May 2026, carrying 12% annual interest and maturing after 12 months. Cost-saving initiatives are under way, but the filing does not quantify their expected effect.